A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
about
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsMonoclonal antibodies targeting CD38 in hematological malignancies and beyondTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsImmune checkpoint blockade for hematologic malignancies: a reviewDilemmas in treating smoldering multiple myeloma.Haematological malignancies: at the forefront of immunotherapeutic innovation.Management of asymptomatic myeloma patients.Targeting B-cell maturation antigen in multiple myeloma.Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Programming the immune checkpoint to treat hematologic malignancies.Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?Control of NK Cell Activation by Immune Checkpoint Molecules.Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Trial watch: Immune checkpoint blockers for cancer therapy.Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.Immunoreceptor tyrosine-based inhibitory motif-dependent functions of an MHC class I-specific NK cell receptor.KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Immunotherapy Strategies Against Multiple Myeloma.Emerging immune targets for the treatment of multiple myeloma.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.Antibody based immunotherapy for multiple myeloma: it's about time.Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma.Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer CellsNatural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy
P2860
Q26751011-8C274BDC-C60D-414A-A053-AE0AEC553C3AQ26766718-8F64B13F-9600-4092-AEFC-A359AF8882D6Q26996518-0E10A09B-E8DB-4B11-AA88-1AE94C9DB500Q33645590-ED371279-E11D-4EAF-BEBB-470524BEF3DBQ34716500-CC7D1867-757B-46B5-B6A3-D28A7C01D472Q35880618-40760A1C-0B9C-4DB8-9AFE-0CDAE582514EQ38264322-0742EAA1-EF82-4B7F-AAA3-37E30292D1ADQ38586922-BB3B4A0A-CC6F-4570-B940-224FC07217CBQ38599353-8719A9ED-6DC4-4FA7-90D0-BE1863E46BCCQ38737970-DF93F971-3FD6-45F7-83D4-86E8A7D759E0Q38806070-33BCD3A6-29A9-43FF-A5CE-457226D3CD37Q38928938-389E4DB7-A3A7-4907-8891-9FF25CEC3D89Q39341524-E3F2DAAD-7E40-4D94-901F-5FFCCA408FEFQ41684097-B6FCB709-51FD-48B6-98ED-BF55FAB8AFB0Q42684464-F4ECF4EB-67F3-448B-86FB-6668218C94CCQ47128718-DFE99DF8-6ACA-4DC1-8A6A-34AA233C7F6CQ47156322-D359BBFC-E4B1-4F47-A65F-A562D007E966Q47393365-B670EDC5-4BCF-4BAA-BB6F-0F0752583BF1Q47550223-03F5C27E-5000-4E33-97D1-731FAC6CDD18Q48327688-77819FF5-19FB-42C9-BB20-9B52DBFB60E6Q48361273-61AE285F-DB91-45A8-A45C-5E57255B08ACQ49830211-EDC73DA6-CCE8-4DF0-9529-DED7E1690051Q49995864-03E298F6-27EE-45EA-9927-B8FF985610F4Q50025144-53272D54-4EF4-4B4A-9C6F-581AA71BEE6AQ50041876-13744DB5-E1B9-42F3-A84F-8D7567412E40Q50204340-FE89B820-048C-491F-9B06-801964007B04Q53349911-73AB26E2-9DFE-49DE-AC36-E74C377C3769Q53693865-1C515F42-4167-4CCB-B897-50FA78A4B91DQ56889003-19354B07-1D95-4D45-91E2-9F488467B182Q58764532-52BBE041-4D73-442B-BDD8-6E68C594AB7A
P2860
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
@en
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
@nl
type
label
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
@en
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
@nl
prefLabel
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
@en
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
@nl
P2093
P2860
P50
P1433
P1476
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
@en
P2093
Alex Minter
Constance Yuan
Diamond Zuchlinski
Elisabet Manasanch
Esther Tan
Irina Maric
Jane Trepel
Katherine R Calvo
Manisha Bhutani
Marcia Mulquin
P2860
P356
10.3324/HAEMATOL.2013.103085
P577
2014-03-21T00:00:00Z